XML 258 R214.htm IDEA: XBRL DOCUMENT v3.22.4
Segment information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of geographical areas [line items]      
Net sales € 42,997 € 37,761 € 36,041 [1]
Pharmaceuticals      
Disclosure of geographical areas [line items]      
Net sales 30,688 26,970 25,674
Pharmaceuticals | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 8,293 5,249 3,534
Pharmaceuticals | Neurology & Immunology      
Disclosure of geographical areas [line items]      
Net sales 2,450 2,324 2,394
Pharmaceuticals | Aubagio      
Disclosure of geographical areas [line items]      
Net sales 2,031 1,955 2,045
Pharmaceuticals | Rare Diseases      
Disclosure of geographical areas [line items]      
Net sales 3,445 3,126 3,011
Pharmaceuticals | Cerezyme      
Disclosure of geographical areas [line items]      
Net sales 707 683 690
Pharmaceuticals | Fabrazyme      
Disclosure of geographical areas [line items]      
Net sales 938 844 817
Pharmaceuticals | Myozyme/Lumizyme      
Disclosure of geographical areas [line items]      
Net sales 958 1,003 948
Pharmaceuticals | Oncology      
Disclosure of geographical areas [line items]      
Net sales 952 912 798
Pharmaceuticals | Jevtana      
Disclosure of geographical areas [line items]      
Net sales 391 455 536
Pharmaceuticals | Rare Blood Disorders      
Disclosure of geographical areas [line items]      
Net sales 1,317 1,141 1,217
Pharmaceuticals | Alprolix      
Disclosure of geographical areas [line items]      
Net sales 504 414 466
Pharmaceuticals | Eloctate      
Disclosure of geographical areas [line items]      
Net sales 580 563 638
Pharmaceuticals | Core Assets      
Disclosure of geographical areas [line items]      
Net sales 6,389 5,768 5,581
Pharmaceuticals | Lovenox      
Disclosure of geographical areas [line items]      
Net sales 1,310 1,486 1,351
Pharmaceuticals | Toujeo      
Disclosure of geographical areas [line items]      
Net sales 1,117 969 933
Pharmaceuticals | Plavix      
Disclosure of geographical areas [line items]      
Net sales 983 929 913
Pharmaceuticals | Non-Core Assets      
Disclosure of geographical areas [line items]      
Net sales 7,222 7,642 8,326
Pharmaceuticals | Lantus      
Disclosure of geographical areas [line items]      
Net sales 2,259 2,494 2,661
Pharmaceuticals | Other non-core assets      
Disclosure of geographical areas [line items]      
Net sales 4,485 4,729 5,111
Pharmaceuticals | Industrial sales      
Disclosure of geographical areas [line items]      
Net sales 620 808 813
Vaccines      
Disclosure of geographical areas [line items]      
Net sales 7,229 6,323 5,973
Vaccines | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 2,285 2,159 2,106
Vaccines | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 2,977 2,628 2,472
Consumer Healthcare      
Disclosure of geographical areas [line items]      
Net sales 5,080 4,468 4,394
Consumer Healthcare | Allergy      
Disclosure of geographical areas [line items]      
Net sales 734 612 617
Consumer Healthcare | Pain Care      
Disclosure of geographical areas [line items]      
Net sales 1,213 1,093 1,051
Consumer Healthcare | Digestive Wellness      
Disclosure of geographical areas [line items]      
Net sales 1,318 1,131 988
Europe      
Disclosure of geographical areas [line items]      
Net sales 9,999 9,759 9,151
Europe | Pharmaceuticals      
Disclosure of geographical areas [line items]      
Net sales 7,157 7,201 6,819
Europe | Pharmaceuticals | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 940 649 386
Europe | Pharmaceuticals | Neurology & Immunology      
Disclosure of geographical areas [line items]      
Net sales 639 638 578
Europe | Pharmaceuticals | Aubagio      
Disclosure of geographical areas [line items]      
Net sales 511 512 473
Europe | Pharmaceuticals | Rare Diseases      
Disclosure of geographical areas [line items]      
Net sales 1,104 1,069 1,010
Europe | Pharmaceuticals | Cerezyme      
Disclosure of geographical areas [line items]      
Net sales 239 244 249
Europe | Pharmaceuticals | Fabrazyme      
Disclosure of geographical areas [line items]      
Net sales 228 223 200
Europe | Pharmaceuticals | Myozyme/Lumizyme      
Disclosure of geographical areas [line items]      
Net sales 408 410 389
Europe | Pharmaceuticals | Oncology      
Disclosure of geographical areas [line items]      
Net sales 239 327 299
Europe | Pharmaceuticals | Jevtana      
Disclosure of geographical areas [line items]      
Net sales 33 112 187
Europe | Pharmaceuticals | Rare Blood Disorders      
Disclosure of geographical areas [line items]      
Net sales 94 81 41
Europe | Pharmaceuticals | Alprolix      
Disclosure of geographical areas [line items]      
Net sales 0 0 0
Europe | Pharmaceuticals | Eloctate      
Disclosure of geographical areas [line items]      
Net sales 0 0 0
Europe | Pharmaceuticals | Core Assets      
Disclosure of geographical areas [line items]      
Net sales 1,917 1,868 1,759
Europe | Pharmaceuticals | Lovenox      
Disclosure of geographical areas [line items]      
Net sales 658 703 656
Europe | Pharmaceuticals | Toujeo      
Disclosure of geographical areas [line items]      
Net sales 421 394 374
Europe | Pharmaceuticals | Plavix      
Disclosure of geographical areas [line items]      
Net sales 101 115 126
Europe | Pharmaceuticals | Non-Core Assets      
Disclosure of geographical areas [line items]      
Net sales 1,637 1,846 2,088
Europe | Pharmaceuticals | Lantus      
Disclosure of geographical areas [line items]      
Net sales 426 474 537
Europe | Pharmaceuticals | Other non-core assets      
Disclosure of geographical areas [line items]      
Net sales 1,129 1,285 1,451
Europe | Pharmaceuticals | Industrial sales      
Disclosure of geographical areas [line items]      
Net sales 587 723 658
Europe | Vaccines      
Disclosure of geographical areas [line items]      
Net sales 1,341 1,225 973
Europe | Vaccines | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 325 306 331
Europe | Vaccines | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 681 729 441
Europe | Consumer Healthcare      
Disclosure of geographical areas [line items]      
Net sales 1,501 1,333 1,359
Europe | Consumer Healthcare | Allergy      
Disclosure of geographical areas [line items]      
Net sales 55 49 51
Europe | Consumer Healthcare | Pain Care      
Disclosure of geographical areas [line items]      
Net sales 555 515 481
Europe | Consumer Healthcare | Digestive Wellness      
Disclosure of geographical areas [line items]      
Net sales 432 389 371
US      
Disclosure of geographical areas [line items]      
Net sales 18,275 14,385 13,465
US | Pharmaceuticals      
Disclosure of geographical areas [line items]      
Net sales 13,694 10,484 9,635
US | Pharmaceuticals | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 6,346 3,971 2,808
US | Pharmaceuticals | Neurology & Immunology      
Disclosure of geographical areas [line items]      
Net sales 1,637 1,482 1,631
US | Pharmaceuticals | Aubagio      
Disclosure of geographical areas [line items]      
Net sales 1,420 1,312 1,448
US | Pharmaceuticals | Rare Diseases      
Disclosure of geographical areas [line items]      
Net sales 1,367 1,142 1,122
US | Pharmaceuticals | Cerezyme      
Disclosure of geographical areas [line items]      
Net sales 194 173 177
US | Pharmaceuticals | Fabrazyme      
Disclosure of geographical areas [line items]      
Net sales 471 395 406
US | Pharmaceuticals | Myozyme/Lumizyme      
Disclosure of geographical areas [line items]      
Net sales 318 373 359
US | Pharmaceuticals | Oncology      
Disclosure of geographical areas [line items]      
Net sales 515 410 368
US | Pharmaceuticals | Jevtana      
Disclosure of geographical areas [line items]      
Net sales 275 253 246
US | Pharmaceuticals | Rare Blood Disorders      
Disclosure of geographical areas [line items]      
Net sales 983 842 837
US | Pharmaceuticals | Alprolix      
Disclosure of geographical areas [line items]      
Net sales 406 332 320
US | Pharmaceuticals | Eloctate      
Disclosure of geographical areas [line items]      
Net sales 450 429 445
US | Pharmaceuticals | Core Assets      
Disclosure of geographical areas [line items]      
Net sales 1,653 1,315 1,413
US | Pharmaceuticals | Lovenox      
Disclosure of geographical areas [line items]      
Net sales 17 29 30
US | Pharmaceuticals | Toujeo      
Disclosure of geographical areas [line items]      
Net sales 283 259 267
US | Pharmaceuticals | Plavix      
Disclosure of geographical areas [line items]      
Net sales 9 9 10
US | Pharmaceuticals | Non-Core Assets      
Disclosure of geographical areas [line items]      
Net sales 1,176 1,281 1,389
US | Pharmaceuticals | Lantus      
Disclosure of geographical areas [line items]      
Net sales 757 861 929
US | Pharmaceuticals | Other non-core assets      
Disclosure of geographical areas [line items]      
Net sales 412 410 438
US | Pharmaceuticals | Industrial sales      
Disclosure of geographical areas [line items]      
Net sales 17 41 67
US | Vaccines      
Disclosure of geographical areas [line items]      
Net sales 3,291 2,762 2,759
US | Vaccines | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 456 470 412
US | Vaccines | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 1,737 1,366 1,575
US | Consumer Healthcare      
Disclosure of geographical areas [line items]      
Net sales 1,290 1,139 1,071
US | Consumer Healthcare | Allergy      
Disclosure of geographical areas [line items]      
Net sales 439 371 361
US | Consumer Healthcare | Pain Care      
Disclosure of geographical areas [line items]      
Net sales 212 196 181
US | Consumer Healthcare | Digestive Wellness      
Disclosure of geographical areas [line items]      
Net sales 144 124 85
Other countries      
Disclosure of geographical areas [line items]      
Net sales 14,723 13,617 13,425
Other countries | Pharmaceuticals      
Disclosure of geographical areas [line items]      
Net sales 9,837 9,285 9,220
Other countries | Pharmaceuticals | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 1,007 629 340
Other countries | Pharmaceuticals | Neurology & Immunology      
Disclosure of geographical areas [line items]      
Net sales 174 204 185
Other countries | Pharmaceuticals | Aubagio      
Disclosure of geographical areas [line items]      
Net sales 100 131 124
Other countries | Pharmaceuticals | Rare Diseases      
Disclosure of geographical areas [line items]      
Net sales 974 915 879
Other countries | Pharmaceuticals | Cerezyme      
Disclosure of geographical areas [line items]      
Net sales 274 266 264
Other countries | Pharmaceuticals | Fabrazyme      
Disclosure of geographical areas [line items]      
Net sales 239 226 211
Other countries | Pharmaceuticals | Myozyme/Lumizyme      
Disclosure of geographical areas [line items]      
Net sales 232 220 200
Other countries | Pharmaceuticals | Oncology      
Disclosure of geographical areas [line items]      
Net sales 198 175 131
Other countries | Pharmaceuticals | Jevtana      
Disclosure of geographical areas [line items]      
Net sales 83 90 103
Other countries | Pharmaceuticals | Rare Blood Disorders      
Disclosure of geographical areas [line items]      
Net sales 240 218 339
Other countries | Pharmaceuticals | Alprolix      
Disclosure of geographical areas [line items]      
Net sales 98 82 146
Other countries | Pharmaceuticals | Eloctate      
Disclosure of geographical areas [line items]      
Net sales 130 134 193
Other countries | Pharmaceuticals | Core Assets      
Disclosure of geographical areas [line items]      
Net sales 2,819 2,585 2,409
Other countries | Pharmaceuticals | Lovenox      
Disclosure of geographical areas [line items]      
Net sales 635 754 665
Other countries | Pharmaceuticals | Toujeo      
Disclosure of geographical areas [line items]      
Net sales 413 316 292
Other countries | Pharmaceuticals | Plavix      
Disclosure of geographical areas [line items]      
Net sales 873 805 777
Other countries | Pharmaceuticals | Non-Core Assets      
Disclosure of geographical areas [line items]      
Net sales 4,409 4,515 4,849
Other countries | Pharmaceuticals | Lantus      
Disclosure of geographical areas [line items]      
Net sales 1,076 1,159 1,195
Other countries | Pharmaceuticals | Other non-core assets      
Disclosure of geographical areas [line items]      
Net sales 2,944 3,034 3,222
Other countries | Pharmaceuticals | Industrial sales      
Disclosure of geographical areas [line items]      
Net sales 16 44 88
Other countries | Vaccines      
Disclosure of geographical areas [line items]      
Net sales 2,597 2,336 2,241
Other countries | Vaccines | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 1,504 1,383 1,363
Other countries | Vaccines | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 559 533 456
Other countries | Consumer Healthcare      
Disclosure of geographical areas [line items]      
Net sales 2,289 1,996 1,964
Other countries | Consumer Healthcare | Allergy      
Disclosure of geographical areas [line items]      
Net sales 240 192 205
Other countries | Consumer Healthcare | Pain Care      
Disclosure of geographical areas [line items]      
Net sales 446 382 389
Other countries | Consumer Healthcare | Digestive Wellness      
Disclosure of geographical areas [line items]      
Net sales € 742 € 618 € 532
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.